Provided herein are gas bubble populations optimized for certain imaging and therapeutic ultrasound uses, methods of preparing such populations, and methods of use thereof.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations, agents and substances for diagnostic imaging; radiopharmaceutical imaging agents for detection, diagnosis and monitoring of Alzheimer's disease, neurological and neurodegenerative diseases and disorders, and brain conditions; diagnostic pharmaceutical preparations, agents and substances for detecting and monitoring of Tau neurofibrillary tangles to aid the evaluation/assessment of Alzheimer's disease and treatments, neurological and neurodegenerative diseases and disorders, and brain conditions
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations, agents and substances for diagnostic imaging; radiopharmaceutical imaging agents for detection, diagnosis and monitoring of Alzheimer's disease, neurological and neurodegenerative diseases and disorders, and brain conditions; diagnostic pharmaceutical preparations, agents and substances for detecting and monitoring of Tau neurofibrillary tangles to aid the evaluation/assessment of Alzheimer's disease and treatments, neurological and neurodegenerative diseases and disorders, and brain conditions
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations, agents and substances for diagnostic imaging; radiopharmaceutical imaging agents for detection, diagnosis and monitoring of Alzheimer's disease, neurological and neurodegenerative diseases and disorders, and brain conditions; diagnostic pharmaceutical preparations, agents and substances for detecting and monitoring of Tau neurofibrillary tangles to aid the evaluation/assessment of Alzheimer's disease and treatments, neurological and neurodegenerative diseases and disorders, and brain conditions
45 - Legal and security services; personal services for individuals.
Goods & Services
providing personal support services for patients; providing online patient medical information in the field of patient care, treatment and drug information, and other resources
6.
COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07D 311/56 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
B01J 19/24 - Stationary reactors without moving elements inside
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention is generally directed towards compositions comprising ascorbic acid or ascorbate salt and an imaging agent, and related methods. In some embodiments, the imaging agent comprises pyridaben or a pyridaben analog attached to an imaging moiety.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Radiopharmaceutical product for the treatment of cancer;
pharmaceutical preparations for the diagnosis and treatment
of oncological diseases and disorders; pharmaceutical
preparations for the treatment of metastatic castration
resistant prostate cancer.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Radiopharmaceutical product for the treatment of cancer;
radiopharmaceutical compounds for the treatment of
neuroendocrine tumors; pharmaceutical preparations for the
treatment of somatostatin receptor-positive neuroendocrine
tumors; pharmaceutical preparations for the diagnosis and
treatment of oncological diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Radiopharmaceutical product for the treatment of cancer;
pharmaceutical preparations for the diagnosis and treatment
of oncological diseases and disorders; pharmaceutical
preparations for the treatment of metastatic castration
resistant prostate cancer.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Radiopharmaceutical product for the treatment of cancer;
radiopharmaceutical compounds for the treatment of
neuroendocrine tumors; pharmaceutical preparations for the
treatment of somatostatin receptor-positive neuroendocrine
tumors; pharmaceutical preparations for the diagnosis and
treatment of oncological diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Radiopharmaceutical product for the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of metastatic castration resistant prostate cancer.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Radiopharmaceutical product for the treatment of cancer; radiopharmaceutical compounds for the treatment of neuroendocrine tumors; pharmaceutical preparations for the treatment of somatostatin receptor-positive neuroendocrine tumors; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Radiopharmaceutical product for the treatment of cancer; radiopharmaceutical compounds for the treatment of neuroendocrine tumors; pharmaceutical preparations for the treatment of somatostatin receptor-positive neuroendocrine tumors; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Radiopharmaceutical product for the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of metastatic castration resistant prostate cancer.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Radiopharmaceutical product for the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of metastatic castration resistant prostate cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Radiopharmaceutical product for the treatment of cancer; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of metastatic castration resistant prostate cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Radiopharmaceutical product for the treatment of cancer; radiopharmaceutical compounds for the treatment of neuroendocrine tumors; pharmaceutical preparations for the treatment of somatostatin receptor-positive neuroendocrine tumors; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Radiopharmaceutical product for the treatment of cancer; radiopharmaceutical compounds for the treatment of neuroendocrine tumors; pharmaceutical preparations for the treatment of somatostatin receptor-positive neuroendocrine tumors; pharmaceutical preparations for the diagnosis and treatment of oncological diseases and disorders
22.
METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS
Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
Provided herein are gas bubble populations optimized for certain imaging and therapeutic ultrasound uses, methods of preparing such populations, and methods of use thereof.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
42 - Scientific, technological and industrial services, research and design
Goods & Services
Promotional services to promote public awareness in the
field of diseases and disorders. Medical research and development services in the field of
diseases and disorders.
25.
LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Promotional services to promote public awareness in the field of diseases and disorders.
(2) Medical research and development services in the field of diseases and disorders.
27.
COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.
C07C 279/04 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
C07D 233/46 - Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms attached to said nitrogen atoms
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07C 257/14 - Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
C07C 279/06 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
C07C 279/08 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
C07C 279/12 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
C07C 281/18 - Compounds containing any of the groups e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
C07C 217/70 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07C 215/60 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 217/70 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 279/06 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
C07C 279/08 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
A pierceable plug for closing off a piercing end of a needle is described herein. The plug has an end that is configured to be pierced by the needle to close off the piercing end of the needle. The plug may be radiation sterilizable and may be made of a material that includes an antimicrobial agent. The plug may be used to close off a needle end that is in fluid communication with a radioactive substance.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Diagnostic imaging and ultrasound contrast agents having
high resolution echo characteristics; diagnostic imaging
agents for use in ultrasound imaging; ultrasound contrast
agents comprising microbubbles for diagnostic imaging and
therapy; therapeutic delivery agents comprising microbubbles
for human use.
Techniques for monitoring a pharmaceutical manufacturing process and making determinations regarding the release of radiopharmaceuticals to health care providers. A data processing system collects data across multiple batches of radiopharmaceuticals, across multiple entities, and/or across multiple stages of the manufacturing process, processes the data, and provides feedback to entities involved in the manufacturing process. In scenarios where quality assurance tests are conducted, data is collected from radiopharmaceutical products before they are shipped, and the data is analyzed to provide the recipients with an indication of whether the radiopharmaceutical products satisfy quality assurance standards. Techniques for analyzing information about a batch manufacturing process and, when a problem occurred during a manufacture of a batch, determining whether to continue to manufacture a next batch in time for delivering and administering to a patient. The detected problem may be investigated and remedied before or during the synthesis of the next batch.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic agents, preparations, and substances for medical purposes; imaging agents, preparations, and substances for medical purposes, namely, ultrasound contrast imaging agents for ultrasound diagnostic imaging; preparations for medical purposes, namely, therapeutic preparations for the treatment of cardiovascular diseases and disorders, neurological diseases and disorders, brain conditions, lung diseases and disorders, and cancer Medical apparatus for use in medical imaging, namely, medical devices used for obtaining physical access to contrast media vials and dispensing the contents of contrast media vials; generator of radioactive technetium for clinical use in nuclear medicine; medical apparatus for use in medical imaging, namely, activation apparatus for use in the preparation of ultrasound contrast imaging agents promoting public awareness in the field of diseases and disorders research and development services in the field of diseases and disorders medical services, namely, radiopharmacy nuclear medicine services; providing medical testing services and information in the field of diagnosis, treatment, and prevention of diseases and disorders
36.
METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS
Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
The present invention generally relates to novel synthetic methods, systems, kits, salts, and precursors useful in medical imaging. In some embodiments, the present invention provides compositions comprising an imaging agent precursor, which may be formed using the synthetic methods described herein. An imaging agent may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07C 303/30 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reactions not involving the formation of esterified sulfo groups
C07C 217/58 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
C07C 255/54 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
C07C 279/10 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by doubly-bound oxygen atoms
C07C 309/73 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
C07C 277/08 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 303/28 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
C07C 309/04 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
The present invention generally relates to methods and system for the synthesis of imaging agents, and precursors thereof. The methods may exhibit improved yields and may allow for the large-scale synthesis of imaging agents, including imaging agents comprising a radioisotope (e.g., 18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
research and development services in the field of diseases and disorders providing medical testing services and information in the field of diagnosis, treatment, and prevention of diseases and disorders
42.
Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk of developing other cardiovascular conditions and assessing the effectiveness of treatment or other intervention for such conditions by determining MMP levels.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A pierceable plug for closing off a piercing end of a needle is described herein. The plug has an end that is configured to be pierced by the needle to close off the piercing end of the needle. The plug may be radiation sterilizable and may be made of a material that includes an antimicrobial agent. The plug may be used to close off a needle end that is in fluid communication with a radioactive substance.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications
A pierceable plug for closing off a piercing end of a needle is described herein. The plug has an end that is configured to be pierced by the needle to close off the piercing end of the needle. The plug may be radiation sterilizable and may be made of a material that includes an antimicrobial agent. The plug may be used to close off a needle end that is in fluid communication with a radioactive substance.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications
47.
Compositions, methods, and systems for the synthesis and use of imaging agents
18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 311/56 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
B01J 19/24 - Stationary reactors without moving elements inside
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
G01N 29/00 - Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic wavesVisualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
Techniques for monitoring a pharmaceutical manufacturing process and making determinations regarding the release of radiopharmaceuticals to health care providers. A data processing system collects data across multiple batches of radiopharmaceuticals, across multiple entities, and/or across multiple stages of the manufacturing process, processes the data, and provides feedback to entities involved in the manufacturing process. In scenarios where quality assurance tests are conducted, data is collected from radiopharmaceutical products before they are shipped, and the data is analyzed to provide the recipients with an indication of whether the radiopharmaceutical products satisfy quality assurance standards. Techniques for analyzing information about a batch manufacturing process and, when a problem occurred during a manufacture of a batch, determining whether to continue to manufacture a next batch in time for delivering and administering to a patient. The detected problem may be investigated and remedied before or during the synthesis of the next batch.
G05D 21/02 - Control of chemical or physico-chemical variables, e.g. pH-value characterised by the use of electric means
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling
18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Methods for isolating Pb and/or Pb isotopes from various sources are provided. Compositions comprising Pb and/or Pb isotopes free of certain amounts of various contaminants are also provided.
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
diagnostic radiopharmaceutical imaging agents, diagnostic ultrasound contrast agents, and therapeutic agents for the treatment of cardiovascular diseases and disorders, neurological diseases and disorders, brain conditions, lung diseases and disorders, and cancer medical devices used for obtaining access to contrast media vials and dispensing the contents of contrast media vials; generator of radioactive technetium for clinical use in nuclear medicine; activation apparatus for agitating an ultrasound contrast agent formulation in a vial for use in the preparation of microspheres, including ultrasound contrast imaging agents for medical purposes medical services, namely, radiopharmacy nuclear medicine services
Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release thereby reducing side effects, improved quantitative data, and/or high affinity for VMAT over prior radiotracers. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.
C07C 217/70 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07C 215/60 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 279/06 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
C07C 279/08 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
diagnostic imaging agents for use in ultrasound imaging; ultrasound contrast agents comprising microbubbles for diagnostic imaging and therapy; therapeutic delivery agents comprising microbubbles for human use
18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07D 311/56 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07F 7/08 - Compounds having one or more C—Si linkages
B01J 19/24 - Stationary reactors without moving elements inside
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Containers for sealing and shielding radioactive fluid are disclosed. Methods of manufacturing such containers are also disclosed. The container is arranged to maintain a fluid tight seal to contain radioactive fluid when subjected to environmental forces, while also permitting a user to manually remove the cap from the container body when desired. In some embodiments, the container includes a container body with an inner chamber, along with an associated cap. The cap forms a fluid tight seal with the body by way of an interference fit between a sealing element and a burnished abutment surface.
G21F 5/015 - Transportable or portable shielded containers for storing radioactive sources, e.g. source carriers for irradiation unitsRadioisotope containers
G21F 5/12 - Closures for containersSealing arrangements
G21F 5/14 - Devices for handling containers or shipping-casks, e.g. transporting devices
65.
BRINGING PHYSIOLOGY AND FUNCTION TO LIGHT ON THE PATHWAY OF PATIENT CARE
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Biochemicals, namely, precursors for use in medical imaging; Imaging agents, imaging preparations and imaging substances for use in medical tomographic imaging; Diagnostic agents, diagnostic preparations and diagnostic substances for use in evaluating patients with known or suspected coronary artery disease
(2) Biochemicals, namely, precursors for use in medical imaging.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Biochemicals, namely, precursors for use in medical imaging; Imaging agents, imaging preparations and imaging substances for use in medical tomographic imaging; Diagnostic agents, diagnostic preparations and diagnostic substances for use in evaluating patients with known or suspected coronary artery disease
(2) Biochemicals, namely, precursors for use in medical imaging.
69.
Contrast agents for applications including perfusion imaging
The present invention is directed, in part, to compounds and methods for imaging the central nervous system or cancer, comprising administering to a subject a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the subject using diagnostic imaging.
18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07C 303/30 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reactions not involving the formation of esterified sulfo groups
C07C 217/58 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
C07C 255/54 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
C07C 279/10 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by doubly-bound oxygen atoms
C07C 309/73 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
C07C 277/08 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 303/28 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
C07C 309/04 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
C07C 277/00 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups
74.
METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS
Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
Provided herein are methods and devices for identifying and/or distinguishing UCA formulations and specifically activating such formulations to produce UCA suitable for in vivo use.
18F). Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like. In some cases, methods for evaluating perfusion, including myocardial perfusion, are provided. Synthetic methods of the invention have also been incorporated into an automated synthesis unit to prepare and purify imaging agents that comprise a radioisotope. In some embodiments, the present invention provides a novel methods and systems comprising imaging agent 1, including methods of imaging in a subject comprising administering a composition comprising imaging agent 1 to a subject by injection, infusion, or any other known method, and imaging the area of the subject wherein the event of interest is located.
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
78.
Lipid-encapsulated gas microsphere compositions and related methods
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
79.
Compositions, methods, and systems for the synthesis and use of imaging agents
18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07F 7/08 - Compounds having one or more C—Si linkages
B01J 19/24 - Stationary reactors without moving elements inside
80.
Compositions, methods, and systems for the synthesis and use of imaging agents
The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
B01J 19/24 - Stationary reactors without moving elements inside
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
C07D 311/56 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07F 7/08 - Compounds having one or more C—Si linkages
Methods for isolating Pb and/or Pb isotopes from various sources are provided. Compositions comprising Pb and/or Pb isotopes free of certain amounts of various contaminants are also provided.
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
C07D 257/02 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07C 259/14 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxyamidine groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07D 209/20 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
83.
Compositions, methods, and systems for the synthesis and use of imaging agents
18F. In some cases, an imaging agent including salt forms (e.g., ascorbate salt) may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07C 303/30 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reactions not involving the formation of esterified sulfo groups
C07C 217/58 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
C07C 255/54 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
C07C 277/08 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
C07C 279/10 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by doubly-bound oxygen atoms
C07C 309/73 - Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 303/28 - Preparation of esters or amides of sulfuric acidsPreparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
C07C 309/04 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
C07C 277/00 - Preparation of guanidine or its derivatives, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups
84.
Lipid-encapsulated gas microsphere compositions and related methods
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
85.
LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
A61K 49/08 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by the carrier
87.
LIPID ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS
Containers for sealing and shielding radioactive fluid are disclosed. Methods of manufacturing such containers are also disclosed. The container is arranged to maintain a fluid tight seal to contain radioactive fluid when subjected to environmental forces, while also permitting a user to manually remove the cap from the container body when desired. In some embodiments, the container includes a container body with an inner chamber, along with an associated cap. The cap forms a fluid tight seal with the body by way of an interference fit between a sealing element and a burnished abutment surface.
Containers for sealing and shielding radioactive fluid are disclosed. Methods of manufacturing such containers are also disclosed. The container is arranged to maintain a fluid tight seal to contain radioactive fluid when subjected to environmental forces, while also permitting a user to manually remove the cap from the container body when desired. In some embodiments, the container includes a container body with an inner chamber, along with an associated cap. The cap forms a fluid tight seal with the body by way of an interference fit between a sealing element and a burnished abutment surface.
Techniques for monitoring a pharmaceutical manufacturing process and making determinations regarding the release of radiopharmaceuticals to health care providers. A data processing system collects data across multiple batches of radiopharmaceuticals, across multiple entities, and/or across multiple stages of the manufacturing process, processes the data, and provides feedback to entities involved in the manufacturing process. In scenarios where quality assurance tests are conducted, data is collected from radiopharmaceutical products before they are shipped, and the data is analyzed to provide the recipients with an indication of whether the radiopharmaceutical products satisfy quality assurance standards. Techniques for analyzing information about a batch manufacturing process and, when a problem occurred during a manufacture of a batch, determining whether to continue to manufacture a next batch in time for delivering and administering to a patient. The detected problem may be investigated and remedied before or during the synthesis of the next batch.
This application relates to a process for making a pharmaceutically acceptable formulation of gadofosveset trisodium monohydrate, wherein the process uses no more than one chromatographic purification for removal of impurities.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
Methods for isolating Pb and/or Pb isotopes from various sources are provided. Compositions comprising Pb and/or Pb isotopes free of certain amounts of various contaminants are also provided.
Methods for isolating Pb and/or Pb isotopes from various sources are provided. Compositions comprising Pb and/or Pb isotopes free of certain amounts of various contaminants are also provided.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
This application relates to a process for making a pharmaceutically acceptable formulation of gadofosveset trisodium monohydrate, wherein the process uses no more than one chromatographic purification for removal of impurities.
C07D 233/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 233/28 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Techniques for monitoring a pharmaceutical manufacturing process and making determinations regarding the release of radiopharmaceuticals to health care providers. A data processing system collects data across multiple batches of radiopharmaceuticals, across multiple entities, and/or across multiple stages of the manufacturing process, processes the data, and provides feedback to entities involved in the manufacturing process. In scenarios where quality assurance tests are conducted, data is collected from radiopharmaceutical products before they are shipped, and the data is analyzed to provide the recipients with an indication of whether the radiopharmaceutical products satisfy quality assurance standards. Techniques for analyzing information about a batch manufacturing process and, when a problem occurred during a manufacture of a batch, determining whether to continue to manufacture a next batch in time for delivering and administering to a patient. The detected problem may be investigated and remedied before or during the synthesis of the next batch.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Techniques for monitoring a pharmaceutical manufacturing process and making determinations regarding the release of radiopharmaceuticals to health care providers. A data processing system collects data across multiple batches of radiopharmaceuticals, across multiple entities, and/or across multiple stages of the manufacturing process, processes the data, and provides feedback to entities involved in the manufacturing process. In scenarios where quality assurance tests are conducted, data is collected from radiopharmaceutical products before they are shipped, and the data is analyzed to provide the recipients with an indication of whether the radiopharmaceutical products satisfy quality assurance standards. Techniques for analyzing information about a batch manufacturing process and, when a problem occurred during a manufacture of a batch, determining whether to continue to manufacture a next batch in time for delivering and administering to a patient. The detected problem may be investigated and remedied before or during the synthesis of the next batch.
The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07D 311/56 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07F 7/10 - Compounds having one or more C—Si linkages containing nitrogen
